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FDA REGULATION AND THE NEW ANTI-AGING PRODUCTS
I. INTRODUCTION
In the decades since the enactment of the Federal Food, Drug, and Cosmetic
Act (the Act)' in 1938, one of the more persistent challenges facing the Food
and Drug Administration (the FDA) has been to apply an old statute to the
regulatory problems generated by new technologies. The development of new
anti-aging skin preparations is a recent example of this phenomenon. Although
potions purporting to make the skin younger have existed for centuries, today's
youth-seekers are spending billions on new products that just might work.2 In
particular, the development of alpha hydroxy acids (AHAs) has been promising.3
Derived from fruit, sugar cane, and milk, AHAs cause the surface layer of dead
skin cells to shed, hastening the appearance of fresh cells. The laboratory results
are inconclusive thus far, but preliminary research shows that some products
may deliver active ingredients to the skin's inner layer, stimulating the produc-
tion of moisturizing acids and cells such as collagen that help to keep the skin
rm.4
The ability of AHAs to penetrate the skin and alter cell structure raises an
important question: does the Act adequately protect consumers from cosmetics
that may work so well as to change the way the body operates? Currently, even
if a skin cream behaves like a drug by aecting the structure or any function of
the body, it will generally be considered a
1
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cosmetic under the Act if the manufacturer refrains claiming that the AHA
product works like a drug. Products classied as cosmetics under the Act are
relatively unregulated; the Act does not subject them to most of the restrictions
imposed upon drugs -
- including mandatory registration, premarket safety and eectiveness test-
ing, premarket FDA approval, and postmarket surveillance to monitor safety.
This paper will address whether the current regulatory environment is ade-
quate to protect consumers both from the economic injuries that may arise from
misleading claims made by AHA manufacturers and from the physical injuries
that may arise from the use of AHAs. Part II describes the current regulatory
environment applicable to AHA products and assesses the FDA's ability to pro-
tect consumers from deception and physical injury. Balancing the health, safety,
and economic benets of increased regulation against its costs to the FDA, to
business, and to consumers, part Ill analyzes the adequacy of this regulatory
environment and concludes that consumers are suciently protected and that
the FDA's human and nancial resources should be expended on more pressing
concerns.
II. REGULATING ANTI-AGING PRODUCTS UNDER TEE ACT
AHA products threaten consumers in two ways. First, they may cause economic
injuries by misleading consumers into believing that AHAs are a guaranteed mir-
acle cure for wrinkles. In fact, scientists have not progressed beyond speculation
as to
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how AHAs work and whether they really ght wrinkles. Second, AHAs may
cause both short-term and long-term physical injuries to consumers. Temporary
rashes and skin irritations have appeared in some AHA users. Moreover, if AHAs
actually penetrate the skin and cause increased cell turnover, scientists fear that
dizziness, headaches, or shortness of breath could result,6 that new cells might
be abnormal, or that the acceleration of skin cell exfoliation might reduce the
skin's natural protection against the elements.7 Like the potential eectiveness
of AliAs, most of these potential dangers are also speculative.
Currently, the FDA may employ three strategies to protect consumers from
both economic and physical injuries caused by AHA products. First, the FDA
can threaten to classify an AHA product as a drug if the manufacturer represents
that it works like a drug. This enforcement strategy protects consumers from
a wrinkle cream's misleading claims, because the manufacturer would rather
refrain from making such claims than to have the FDA call its product an un-
approved new drug and force it from the market.8 If the manufacturer does not
make drug claims, the FDA can protect consumers by enforcing the adulteration
or misbranding provisions of the Act.9 The adulteration provision protects con-
sumers against cosmetics that contain any poisonous or deleterious substance
which may render it injurious to users. If research shows AliAs to be dangerous,
then the FDA can prohibit or restrict the use of AliAs in cosmetic products.
The
3
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misbranding provision protects consumers from economic injuries by pro-
hibiting cosmetic labeling that is false or misleading in any particular, and it
protects against physical injuries by requiring conspicuous labeling of the manu-
facturer's name, place of business, the product's ingredients, and, in some cases,
warnings about the product.
A. Classication of AHAs as Drugs
The FDA's main line of attack against wrinkle creams has been to argue that
manufacturers' representations about how the products work render the prod-
ucts drugs under the Act. Classifying a cosmetic product as a drug and threat-
ening the manufacturer with seizure actions is an eective strategy to protect
consumers against economic injuries. Because of the enormous costs of the drug
approval process, cosmetic companies have a strong incentive to keep an AHA
product classied as a cosmetic. Thus, manufacturers will refrain from the most
outrageous unproven claims about AliAs, such as Avon's claims that its Mo-
mentum cream accelerates normal cell renewal rate . helps fresh new skin cells
surface faster ... ~h]elps prevent lines and wrinkles ... [w]orks beneath skin's
surface to help prevent cell destruction ... and help us] maintain the integrity
of fresh, new cells.10 Because of the FDA's threats, consumers are less likely to
be deceived into thinking that the products do more than merely enhance the
appearance. 11
Under the Act, an anti-aging product may be classied
4
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either as a drug or as a cosmetic, or as both, depending not on the product's
inherent properties, but rather on the product's intended use.'2 Under the Act,
cosmetics are intended to be rubbed, sprinkled, or sprayed on, introduced into,
or otherwise applied to the human body ... for cleansing, beautifying, promoting
attractiveness, or altering the appearance
,'~ while drugs are intended for use in the diagnosis, cure, mitigation, treat-
ment, or prevention of disease
.. [or] intended to aect the structure or any function of the body .... ~ In
distinguishing drugs from cosmetics, the FDA has focused on the latter part of
the drug denition {i.e., whether a product is intended to aect the structure
of the body.
Because even water, when applied to the skin, temporarily changes the skin's
structure, the FDA and the courts have distinguished drugs from cosmetics by
focusing on a product's intended use, which can be determined by examining the
labeling, advertising, and other circumstances surrounding the manufacturer's
representations about the product.'5 This intended use doctrine means that a
product utterly lacking of drug characteristics nevertheless will be classied as a
drug if the manufacturer claims that the product acts like a drug.'6 Conversely,
cosmetic products that may behave like drugs will generally be classied as
cosmetics, provided that the manufacturer makes no drug claims about the
product.'7 Thus,
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the inclusion of biologically active agents does not in itself make a cosmetic
product a drug: a product is a drug only if a manufacturer makes drug claims
about it or if a product contains substances in concentrations known actually
to aect the structure of the body.'8
In the late 1960s, before AliAs appeared, the FDA sought to classify cosmet-
ics that claimed to smooth, reduce, or prevent wrinkles as drugs. Classifying
the cosmetic product as a drug allowed the FDA to seize it, because a drug
cannot be sold until FDA approval or until the manufacturer demonstrates that
it is generally recognized as safe and eective by qualied experts. 's
In the three published seizure actions instituted by the FDA against wrinkle
creams, the FDA was successful in two cases. In United States v. An Article ...
Sudden Change,20 the Second Circuit upheld the FDA's position, that (r]egardless
of the actual physical eect of a product, it will be deemed a drug for purposes
of the Act where the labeling and promotional claims show intended uses that
bring it within the drug denition.2' Applying the ignorant, the unthinking,
and the credulous22 consumer standard rather than a reasonable woman stan-
dard, the court analyzed Sudden Change's claims that the product would lift
out pus and give a face lift without surgery. The court concluded that these
claims would lead an ignorant, unthinking, or credulous person to believe that
the product was
6
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intended to act as a drug by aecting the body's structure.23 The Third
Circuit reached a similar result in United States
v. An Article ... Line Away,24 because the manufacturer's promotional ma-
terials contained strong therapeutic implications that exceeded the bounds of
mere puery.25 Specically, the manufacturer boasted that the product was
made in a pharmaceutical laboratory and that the product was 'super active'
and 'amazing,' creating a 'tingling sensation' when 'at work', 'tightening' the
skin and 'discouraging new wrinkles from forming.' ,,26
In United States v. An Article ... Helene Curtis MaQic Secret ... ,i27
however, the Maryland federal district court rejected the FDA's attempt to clas-
sify a wrinkle cream as a drug. Finding Magic Secret's claim that it was a 'pure
protein' which causes an 'astringent sensation' to be less exaggerated than those
reported in Line Away and Sudden ChanQe, the court concluded that even the
'ignorant, unthinking and credulous' consumer would be capable of recognizing
that the product could do no more than to alter the appearance. 28
Armed with the principles established by these precedents and faced with an
array of new cosmetic products, the FDA in the late 1980s resumed its attack on
products accompanied by physiological claims about ghting the aging process.
In 1987, the FDA dispatched regulatory letters to more than twenty cosmetic
companies, informing them that certain claims would
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render their products new drugs marketed without an approved new drug
application and requesting { under the threat of seizures or injunctions { correc-
tion of the violations.29 In response to some of the companies' objections and
questions, the FDA wrote a letter in November 1987 to articulate the dierence
between drug claims and cosmetic claims. According to the FDA, any claim
that a product will aect the body { even temporarily { in a physiological way
will constitute a drug claim. Specically,
claims that a product counteracts, retards, or controls aging or the aging
process, as well as claims that a product will rejuvenate, repair, or renew the
skin are drug claims .... [A]lso, all of the examples
[that] allege an eect within the epidermis as the basis for a temporary
benecial eect on wrinkles, lines, or ne lines are unacceptable. A claim such
as molecules absorb ... and expand, exerting upward pressure to 'lift' wrinkles
upward is a claim for inner, structural change.30
The FDA described acceptable claims for cosmetic products as relating to a
physical (as opposed to a physiological) eect on the appearance or the feel of
the skin. Therefore, a skin cream would remain a cosmetic if it claims to
temporarily improve the appearance of ... outward signs of aging ... , to cover
up the signs of aging, to improve the appearance by adding color or luster to
the skin, or otherwise to aect the appearance by physical means. . [A] product
that claims to improve or maintain temporarily the appearance or the feel of the
skin ... , [or] a product that claims to moisturize or soften the skin is a cosmetic
31
The FDA's regulatory letters prompted most of the companies to refrain
from making drug claims, advancing the FDA's goal of protecting consumers
from deceptive marketing. Other manufacturers, however, continue to market
their products with
8
8604-03-92 9
drug-like claims { probably with the expectation that the FDA does not
place a high priority on regulating cosmetics.32 Thus, the FDA's strategy of
threatening to classify as drugs those cosmetic products that claim to aect the
skin's physiology is at least somewhat eective against the threat of economic
harm to consumers. In addition, consumer safety is relatively unprotected by
the classication strategy, because a product can generally avoid being classied
a drug so long as the manufacturer refrains from any drug claims and so long
as the physiological eect of AliAs on the skin's structure remains unknown.
B. Regulation of AliAs Under the Adulteration Provision.
Provided that an AHA manufacturer claims that its product enhances the
appearance by physical but not phvsiolo~ical eect,33 a cosmetic generally may
contain biologically active agents without becoming a drug.34 In other words,
a cosmetic may actually aect the structure of the body so long as the manu-
facturer does not represent that it does so. This does not mean, however, that
cosmetics are free to include whatever substances they choose { the Act protects
consumer safety by authorizing FDA action against adulterated cosmetics. ,,36
A cosmetic is deemed adulterated if it contains a substance that may make
the product injurious to users when used according to the label or in its cus-
tomary fashion.
9
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Unfortunately, protecting consumers from injuries that may arise from cos-
metics under this provision is dicult. Court-action against an allegedly unsafe
cosmetic requires the FDA to meet a high burden of proving injury, and rule-
making is slow.38 Cosmetic companies are not required to register their plants
or products, to le data on the ingredients in their products, to le reports of
cosmetic-related injuries, nor to test their products for safety.39 Even if the FDA
requests safety information, a cosmetic company can refuse to provide it. Under
the current voluntary reporting system, as of 1990, fewer than 40 percent of cos-
metics manufacturers had registered their plants with the FDA, and only about
3 percent of cosmetics distributors had led any injury reports.40 Because of
limited resources, the relative safety of cosmetics, and industry self-regulation,
the FDA has not conducted independent investigations on very many cosmetic
products. Instead, the FDA decides which cosmetics to investigate by relying
on the consumer complaints it receives directly and on the scientic literature.4'
With respect to AliAs in particular, the FDA has adopted a wait-and-see pos-
ture because of the extremely few consumer complaints it has received about
AliAs.42 The FDA plans to reassess this policy when further research develops,
including a report on AHAs that the Cosmetics Ingredient Review Board will
release later in l995.~~
C. Regulation of AHAs Under the Misbranding Provision.
Another way for the FDA to protect consumers against both
10
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economic and physical injuries arising from AliAs is to enforce the Act's
provisions regarding misbranded cosmetics.44 Consumer economic injuries can
be prevented by prohibiting manufacturers from using labeling that is false or
misleading in any particular.45 Consumer physical safety can be enhanced by
requiring warning labels or by seizing (or threatening seizure of) AHA products
that lack warning labels, if the FDA can show that AHAs present a substantial
risk of injury or illness from any handling or use that is customary or usual.46
Currently, manufacturers must label cosmetics with a list of ingredients in de-
scending order of predominance, with the exception of avors and fragrances.47
This regulation does little to help consumers distinguish products with varying
concentrations of AliAs, making it dicult for consumers to know how powerful
a product might be.48 A misbranding regulation also requires cosmetics that
have not been adequately substantiated for safety prior to marketing to con-
tain a warning to that eect.49 This provision is dicult to enforce, however,
because the FDA lacks authority to require safety testing and injury reporting
- - making it dicult for the FDA to argue that safety has not been adequately
substantiated.
III. ANALYSIS AND CONCLUSIONS
Despite the limits on the FDA's ability to regulate cosmetics in an age when
cosmetics increasingly are taking on the attributes of drugs, the social costs of
increased FDA regulation
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far outweigh the safety and economic benets. Advocates of increased FDA
regulation of cosmetics have advanced two primary concerns: protecting con-
sumers from unsafe products and protecting consumers from deceptive practices.
Both of these goals are substantially satised under the current system; regulat-
ing cosmetics more strictly would increase the benets only marginally. When
these marginal benets are weighed against the costs of increased regulation,
including the diversion of FDA resources from more important public health
issues, the arguments for increased regulation fail.
In light of recent developments in cosmetics technology, consumer advocates
argue that it is time to reassess the ecacy of a regulatory regime constructed
over fty years ago. Powerful new products like AliAs are reaching the market
with no proof of safety, possibly endangering consumers with unknown side
eects. Also, clever marketing has lured consumers to spend billions of dollars on
products that have not demonstrated that they actually do anything. Consumer
advocates, therefore, have proposed to amend the Act in order to give the FDA
more authority over cosmetics. Legislative proposals include the creation of a
new cosmeceutical category, consisting of cosmetics with drug characteristics.
Any so-called cosmeceutical would be required to seek premarket approval and
to undergo safety testing.50 Other proposals would increase the regulation of all
cosmetics by requiring manufacturers to register with the FDA, keep adequate
12
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safety data, and le injury reports.5' Others simply argue that the FDA
should increase its policing of the cosmetics industry under existing laws.
Increased regulation would not prevent a signicant number of economic
injuries. The misbranded cosmetics provision of the Act already prohibits de-
ceptive cosmetic labels, and the FDA prevents outrageous physiological claims
about cosmetics by threatening to classify the oending cosmetics as drugs. The
FDA's ability to protect consumers against economic injury is supplemented by
the Federal Trade Commission's authority over advertising, as well as by mod-
ern consumers' ability to take cosmetic puery with a grain of salt. Increased
regulation, however, would give the FDA more information about products and
manufacturers, enabling the FDA to enforce the misbranding provision more
eectively. Additionally, requiring cosmeceuticals to meet the same standards
as drugs would entail premarket proof of ecacy { forcing products that do not
work from the market and preventing consumers from wasting money on useless
products.
Although protecting consumers from deceptive practices is important, the
FDA's primary role is to guard public health and safety. Accordingly, the most
forceful argument for any proposal to increase the regulation of cosmetics is
that physical injuries might be prevented. Premarket safety testing and FDA
approval for cosmeceuticals would obviously decrease the risk of injury
13
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from AliAs by keeping them o of the market, perhaps permanently. The
milder proposal { requiring registration of cosmetics manufacturers with the
FDA and disclosure of safety data and injury reports { would bolster the FDA's
ability to gather information about cosmetic products. The FDA could use this
information to keep an eye on y-by-night manufacturers, to seize cosmetics
that are injurious to users, or to publicize warnings about bad manufacturers
and products.
Despite the enhanced safety that would accompany increased regulation, the
current system adequately, if not perfectly, protects consumer safety. On the
whole, cosmetics are safe products that have caused remarkably few serious in-
juries. Whether the FDA threatens to classify a cosmetic as a drug or chooses
to enforce the adulterated cosmetics provision of the Act, the FDA is capable of
addressing the most serious hazards posed by cosmetics. Thus, premarket FDA
approval would probably bring only minimal additional safety. In other words,
increased regulation might prevent a few temporary rashes, but it is unlikely
to prevent any serious harms or deaths. Moreover, voluntary registration and
industry self-regulation work fairly well. A large majority of cosmetics on the
market are produced by large manufacturers who voluntarily register with the
FDA and le injury reports.52 Also under the aegis of self-regulation, harmful
ingredients have been removed from the market. In fact, the Cosmetics Ingre-
dient Review Board is currently reviewing the
14
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safety of AliAs.
Even if one is persuaded that increased regulation would substantially im-
prove the FDA's ability to protect consumers, the costs of increased regulation
are unreasonable. Increased regulation would impose substantial costs on the
cosmetics industry, many of which would necessarily be externalized to con-
sumers. Requiring premarket safety testing and FDA approval of cosmetics, for
example, would take years and cost millions of dollars. These costs, as well as
the costs of decreased competition resulting from products exiting the market,
would necessarily pass to consumers. In the years prior to approval, regulation
would deprive consumers of the ability to purchase AHA products altogether.
If approval ever comes, AHA products would be signicantly and perhaps pro-
hibitively more expensive. In a free market, consumers would probably prefer
cheaper products available now than more expensive (and probably not much
safer) products available later. Ecient regulation should match what con-
sumers would be willing to pay for, and few would willingly spend so much for
such marginal potential increases in safety.
Mandatory registration and safety/injury disclosure to the FDA, however,
would not unduly burden the cosmetics industry and the consumer. Providing
the FDA with more information would increase the agency's ability to enforce
the laws against drug claims, misbranding, and adulteration. Nevertheless,
requiring the FDA to use this information to regulate cosmetics more
15
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stringently or, more importantly, requiring the FDA to approve cosmeceu-
ticals prior to marketing, imposes an unreasonable burden on the government's
resources.
As an agency with limited resources, the FDA cannot attack all public health
problems with equal vigor. Rather, it must allocate its human and nancial
resources to the most pressing issues { preventing the most injuries within the
constraints imposed by a limited budget and limited time. Because cosmetics
are on balance safer than drugs, foods, and medical devices, the FDA pays
relatively little attention to cosmetics. Instead, the FDA confronts life-or-death
issues such as AIDS, new life-saving drugs, and the threat of poisons in the
nation's food supply. The FDA should not focus its attention and resources
away from these problems unless by doing so the public health is signicantly
enhanced. Cosmetics in general, and AIfAs in particular, are extremely unlikely
to cause any serious, permanent injuries. Therefore, requiring the FDA to
regulate cosmetics more stringently than it already does would be a mistake:
its costs far outweigh any benets.
In the nal analysis, all of the issues in food and drug law require us to
ask how much risk is acceptable in our society. The potential ability of AHAs
to behave like drugs raises a serious question: does a statute written in 1938
adequately regulate the risks presented by the cosmetics products of the 1990s?
Ultimately, we must accept that the Act protects us
16
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incompletely; some risks { such as those presented by AliAs {will remain
exposed. Even though AliAs might cause some economic and physical injuries,
however, the current regulatory environment adequately addresses the most
serious problems that they present. Increasing regulation would cause only
marginal reductions in risk, and at an unreasonable cost. Therefore, the current
system governing cosmetics undoubtedly leaves risks, but they are risks that we
can live with.
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